Evanson Financial LLC Buys Shares of 50,000 CryoPort, Inc. $CYRX

Evanson Financial LLC purchased a new position in shares of CryoPort, Inc. (NASDAQ:CYRX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,000 shares of the company’s stock, valued at approximately $785,000.

Several other hedge funds and other institutional investors have also modified their holdings of CYRX. LPL Financial LLC increased its position in shares of CryoPort by 6.6% in the 4th quarter. LPL Financial LLC now owns 23,306 shares of the company’s stock valued at $224,000 after purchasing an additional 1,433 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of CryoPort by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock valued at $136,000 after purchasing an additional 1,557 shares during the period. State of Wyoming boosted its holdings in shares of CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock valued at $106,000 after acquiring an additional 3,301 shares during the period. Basepoint Wealth LLC acquired a new stake in CryoPort during the 4th quarter worth $34,000. Finally, BNP Paribas Financial Markets grew its position in CryoPort by 55.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock worth $113,000 after purchasing an additional 4,225 shares during the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

CryoPort Stock Up 2.8%

NASDAQ CYRX opened at $15.12 on Friday. The stock has a market capitalization of $762.05 million, a P/E ratio of -16.80 and a beta of 1.89. CryoPort, Inc. has a 52-week low of $7.51 and a 52-week high of $16.89. The firm has a 50-day moving average price of $15.49 and a 200 day moving average price of $11.92.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.13%. The business had revenue of $48.97 million during the quarter, compared to analysts’ expectations of $48.18 million. On average, equities research analysts expect that CryoPort, Inc. will post -0.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on CYRX shares. BTIG Research lifted their price objective on shares of CryoPort from $17.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Weiss Ratings reissued a “hold (c-)” rating on shares of CryoPort in a report on Monday. Jefferies Financial Group set a $13.50 price target on CryoPort in a research report on Monday, June 8th. Craig Hallum upped their price objective on CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, June 3rd. Finally, Guggenheim increased their price objective on CryoPort from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, CryoPort presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Insider Activity

In related news, CFO Robert Stefanovich sold 169,427 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the transaction, the chief financial officer owned 109,850 shares of the company’s stock, valued at $1,787,259.50. This represents a 60.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ramkumar Mandalam sold 23,214 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $15.44, for a total value of $358,424.16. Following the completion of the transaction, the director owned 67,894 shares of the company’s stock, valued at $1,048,283.36. The trade was a 25.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 227,641 shares of company stock valued at $3,622,515 in the last three months. 9.50% of the stock is currently owned by company insiders.

CryoPort Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.